Clinical trials: in Pakistan
Hepatitis B, Chronic
An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated.
- Trial name
- NCT01011738
- Where
- 249 sites in Austria, Bahrain and 25 more
- Volunteers
- 1,842 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
This prospective, multicenter, observational cohort study will evaluate the efficacy and safety of pegylated interferon alfa (peginterferon alfa) (e.g.
- Trial name
- NCT01447446
- Testing
- Peg-IFN Alfa-2a, Peg-IFN Alfa-2b, Ribavirin
- Where
- 271 sites in Belgium, Egypt and 25 more
- Volunteers
- 4,442 people
- Sponsor
- Hoffmann-La Roche
Purpura, Thrombocytopaenic, Idiopathic
LENS - Long-term Eltrombopag Observational Study
A long term observational ocular safety study in adults who have received study medication (either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag.
- Trial name
- LENS (NCT00643929)
- Testing
- Eltrombopag
- Where
- 71 sites in United States, Australia and 19 more
- Volunteers
- 164 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00334152
- Testing
- casopitant
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 515 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Breast
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
This phase II study will evaluate and compare the efficacy and tolerability of two dose schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with advanced or metastatic breast cancer.
- Trial name
- NCT00089999
- Testing
- Lapatinib
- Where
- 31 sites in United States, Chile and 9 more
- Volunteers
- 138 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
- Trial name
- NCT00268216
- Testing
- Salmeterol 50mcg/ Fluticasone Propionate 500mcg
- Where
- 459 sites in United States, Argentina and 42 more
- Volunteers
- 6,228 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice.
- Trial name
- A1chieve® (NCT00869908)
- Testing
- insulin aspart, insulin detemir, biphasic insulin aspart
- Where
- 22 sites in Algeria, Argentina and 20 more
- Volunteers
- 66,726 people
- Sponsor
- Novo Nordisk A/S
Congenital Bleeding Disorder, Congenital FVII Deficiency
Treatment of Congenital Factor VII Deficiency
This study is conducted globally. The aim of this study is to describe the treatment modalities and outcomes of bleeding episodes, surgery and prophylaxis in patients with factor VII (FVII) deficiency in addition to evaluate the…
- Trial name
- F7CONDEF (NCT01779921)
- Testing
- activated recombinant human factor VII, Fresh frozen plasma (Source unspecified), Plasma-derived FVII (LFB)
- Where
- 16 sites in United States, France and 14 more
- Volunteers
- 163 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries
This study is conducted in Asia. The aim of this observational study is to investigate the safety and efficacy of insulin detemir as add-on therapy in type 2 diabetic patients who are using oral antidiabetic drugs.
- Trial name
- BO2NE (NCT00842192)
- Testing
- insulin detemir
- Where
- 4 sites in Israel, Jordan and 2 more
- Volunteers
- 2,155 people
- Sponsor
- Novo Nordisk A/S
Asthma
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
- Trial name
- NCT00163527
- Testing
- Roflumilast
- Where
- 24 sites in United States, Austria and 22 more
- Volunteers
- 2,054 people
- Sponsor
- AstraZeneca
Blood Coagulation Disorders, Hemophilia A
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
The study will assess the pharmacokinetics (part A) safety, tolerability, and efficacy of prophylaxis treatment (2 to 3 times a week) (part B) with BAY81-8973 over a one year period (split into two six month treatment periods).
- Trial name
- Leopold I (NCT01029340)
- Testing
- Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 60 sites in United States, Argentina and 20 more
- Volunteers
- 74 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin
This study will evaluate the longer-term glycemic effect of two medicines approved for initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2 study visits), followed by an 80 week double-blind…
- Trial name
- NCT00386100
- Testing
- Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd)
- Where
- 116 sites in United States, Argentina and 7 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g.
- Trial name
- NCT01344889
- Where
- 260 sites in Albania, Algeria and 23 more
- Volunteers
- 4,459 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan
This observational study will provide an opportunity to document local patterns of susceptibility, patient profile, and usefulness of screening in postmenopausal patients coming to gynecology outpatient clinics in Pakistan.
- Trial name
- NCT02422069
- Where
- 8 sites in Pakistan
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Metabolic Syndrome X
Study In Patients With Dyslipidaemia
Study in patients with dyslipidaemia.
- Trial name
- NCT00264667
- Testing
- GW677954
- Where
- 50 sites in Argentina, Australia and 11 more
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Postoperative
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
- Trial name
- NCT00326248
- Testing
- GW679769 (casopitant)
- Where
- 58 sites in United States, Canada and 9 more
- Volunteers
- 482 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Hepatocellular
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
- Trial name
- GIDEON (NCT00812175)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in United States, Canada and 37 more
- Volunteers
- 3,371 people
- Sponsor
- Bayer
Breast Cancer
An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer
This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer.
- Trial name
- XEPAD (NCT01725386)
- Testing
- Capecitabine
- Where
- 15 sites in Pakistan
- Volunteers
- 274 people
- Sponsor
- Hoffmann-La Roche
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline